NLGIA
TEVA icon

Nippon Life Global Investors Americas’s Teva Pharmaceuticals TEVA Stock Holding History

Nippon Life Global Investors Americas’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-515,960
Closed -$8.09M – 154
2019
Q1 		$8.09M Sell
515,960
-99,670
-16% -$1.76M 0.65% 53
2018
Q4 		$9.49M Buy
615,630
+485,900
+375% +$9.96M 0.82% 41
2018
Q3 		$2.79M Buy
+129,730
New +$3.01M 0.21% 104

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nippon Life Global Investors Americas's TEVA Position: Q2 2019 in Review

Nippon Life Global Investors Americas sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 515,960 shares — an estimated $8.09M sold.

Nippon Life Global Investors Americas first reported a position in TEVA in Q3 2018 and held it in 3 quarters. The position peaked at $9.49M in Q4 2018. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Nippon Life Global Investors Americas reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Nippon Life Global Investors Americas sold 515,960 Teva Pharmaceuticals shares in Q2 2019, an estimated $8.09M.
  • Nippon Life Global Investors Americas first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Nippon Life Global Investors Americas's Teva Pharmaceuticals position peaked at $9.49M in Q4 2018.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Nippon Life Global Investors Americas's 13F filing for Q2 2019, filed 23 Jul 2019.